Abstract: The use of isoquinoline derivatives for the treatment of glaucoma or ocular hypertension. The isoquinoline derivatives are of formula I ##STR1## wherein R.sub.1 is a hydrogen or a C.sub.1 -C.sub.6 alkyl group and R.sub.2 is a C.sub.1 -C.sub.6 alkyl group. The stability of the isoquinoline derivatives when used in the form of a solution is improved by incorporating therein compounds having a phenolic hydroxyl group and/or glycols serving as a stabilizer.

Abstract: A process of preparing l-biopterin is disclosed which comprises the steps of:Subjecting to selective Grignard reaction D-ribose having the hydroxyl groups in the 2- and 3-positions protected by an acetal group to give 6-deoxy-3,4-O-alkylidene allitol;subjecting the 1- and 2-positions of said allitol to oxidative cleavage to form 5-deoxy-2,3-O-alkylidene-L-ribose followed by deacetalization to give 5-deoxy-L-ribose;reacting 5-deoxy-L-ribose with a hydrazine compound to form a 5-deoxy-L-ribose hydrazone compound; andsubjecting said hydrazone compound to condensation reaction with an acid addition salt of 4-hydroxy-2,5,6-triaminopyrimidine followed by oxidation.

Abstract: Compounds are disclosed of the formula ##STR1## wherein R.sub.1 is hydrogen or C.sub.1 -C.sub.6 alkyl;Y is --CH.sub.2 --, --O--, ##STR2## R.sub.2 is C.sub.1 -C.sub.6 alkyl; C.sub.2 -C.sub.6 alkenyl; C.sub.3 -C.sub.6 cycloalkyl; phenyl which may be mono- or di-substituted on the phenyl ring with C.sub.1 -C.sub.6 alkoxy; aralkyl which may be mono- or di-substituted on the aromatic ring with C.sub.1 -C.sub.6 alkoxy; diphenylmethyl; carboalkoxy; or an O- or N-heterocyclic radical which is linked to the nitrogen atom via carbonyl or carbonylmethylene;m is 2 or 3;and n is 0 or 1, and physiologically acceptable acid addition salts thereof. The compounds of formula (I) are of a blood flow-increasing action and can be used for the therapy or prevention of diseases in the cardiovascular system.

Abstract: 4(3H)-Quinazolinone derivative of formula (I) are provided. ##STR1## wherein R.sub.1 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group, an aryl group, a substituted aryl group, or an aralkyl group; R.sub.2 is a C.sub.1 -C.sub.6 alkylamino group, a phenyl group, a substituted phenyl group, or a 5- or 6-membered heterocyclic group containing one or more N, O or S as a hetero atom or atoms, said heterocyclic group optionally being substituted or fused with a benzene ring; n is 1 or 2; or R.sub.2 represents a geranyl group or a dipyridylmethyl group together with the group --(CH.sub.2).sub.n --; and X is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or a halogen atom, and pharmaceutically acceptable acid addition salts thereof. They are useful as antiucler agents.

Abstract: Polyprenols and polyprenyl phosphates are of the formula ##STR1## wherein ##STR2## represents a trans-isoprene unit, ##STR3## represents a cis-isoprene unit, ##STR4## represents a dihydroisoprene unit, l is an integer of 2 to 8, m is 0 or an integer of 5 to 18, n is 0 or 1, the sum of l and m is in the range of 8 to 20, and X represents a hydrogen atom or --PO.sub.3 MM' wherein M and M' may be the same or different and each is a hydrogen atom or a monovalent cation or both M and M' together form a divalent cation. They are useful as a medicament for the inhibition of tumor metastasis.

Abstract: A pharmaceutical oil-in-water type microemulsion having an action of potentiating the activities of anti-cancer agents, said micro-emulsion comprises fine particles of a vegetable oil or a triglyceride of a medium-chain fatty acid having 8 to 12 carbon atoms containing 0.1 to 10% (w/v) of N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine malate of formula (I) below, ##STR1## an aqueous medium, and, 0.05 to 25% (w/v) of a physiologically acceptable phospholipid for dispersing said fine particles in said aqueous medium.

Abstract: Compounds are disclosed of the formula ##STR1## wherein R.sub.1 is hydrogen; C.sub.1 -C.sub.6 alkyl; C.sub.3 -C.sub.6 cycloalkyl or diphenylmethyl;Y is --NH(CH.sub.2).sub.n --R.sub.2 or ##STR2## R.sub.2 is OH or --ONO.sub.2 ; l is 2 or 3; m is 0 or 1; and n is 2 to 8; andphysiologically acceptable acid addition salts thereof. The compounds of formula (I) are of a blood flow-increasing and hypotensive actions and can be used for the therapy or prevention of diseases in the cardiovascular system.

Abstract: A mixer includes an agitating means and a material scraping means in a spherical casing. A mixer further includes a cracking-dispersing means for an easily cohesive powder or an impalpable powder. If crushing of particles need be restricted to a moderate level, the mixer includes either one the above mixers as a mixer main body and an angle setting means for setting the tilt the mixer main body at a given angle.The above mixers may preferably be used for agitating and mixing a powdery or granular material of all kinds, particle sizes, and specific gravities ranging from an easily cohesive powder or an impalpable powder to particles with which it is preferable to restrict a crushing level.

Abstract: Quinoxaline derivatives of formula (I) are provided. ##STR1## wherein A is a hydrogen atom or 2-quinoxalyl group, B is 2-pyridyl or 4-quinolyl group and n is 0 or 1, or a pharmaceutically acceptable acid addition salt thereof. They are useful as antiulcer agents.

Abstract: 2-Pyridylmethylthio derivatives of formula (I) are provided. ##STR1## wherein A represents 4-methyl-2-quinazolinyl, 4-(2-pyridylmethylthio)-1-phthalazinyl or 4-oxo-3-phenyl-3,4-dihydropyrido[2,3-d]pyrimidine-2-yl, or a pharmaceutically acceptable acid addition salt thereof. They are useful as antiulcer agents.

Abstract: Anti-ulcer agents containing isoprenoid derivatives are provided. The isoprenoid derivatives are represented by the formula: ##STR1## wherein: R represents a group of formula ##STR2## In the above formula, R.sub.1, R.sub.2 and R.sub.3 may be the same or different each other and each represents a hydrogen atom, a hydroxy group, a lower alkanoyloxy group, a lower alkyl group or a lower alkoxy group, provided that two or more of them do not represent hydrogen atoms at the same time; R.sub.4 and R.sub.5 may be the same or different each other and each represents a hydrogen atom, a hydroxy group or a lower alkanoyloxy group represents the signal or the double bond between the carbon atoms; m represents 0 or 1; n represents 0 or an integer of from 1 to 9, provided that the sum of m and n is an integer of from 1 to 9.

Abstract: Disclosed are a compound of the formula ##STR1## wherein R.sup.1 is C.sub.1 -C.sub.6 alkyl or a group --(CH.sub.2).sub.n COOR.sup.3 in which n is an integer of 1 to 4 and R.sup.3 is hydrogen or C.sub.1 -C.sub.6 alkyl, and R.sup.2 is a group --CH.dbd.CH--R.sup.4 or --CH.sub.2 --CH.sub.2 --R.sup.4 in which R.sup.4 is substituted or unsubstituted phenyl or a substituted or unsubstituted 5-membered heterocyclic group, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. The compounds have an excellent chemical mediator inhibitory activity.

Abstract: Compounds are described of formula (I) ##STR1## wherein R.sup.1 is a hydrogen atom, an alkyl group, an alkoxy group, a dialkylamino group or a halogen atom; n is 1 to 4; R.sup.2 is a hydrogen atom, an alkyl group, an unsubstituted or substituted aminoalkyl group, an acyl group, an unsubstituted or substituted aralkyl group, a carboxyalkyl group, an alkoxycarbonyalkyl group or ##STR2## wherein X is an unsubstituted or substituted-phenyl, -benzyl, -benzoyl or -furoyl group; A is -NR.sup.3 - where R.sup.3 is hydrogen or alkyl, an alkylene or an alkylidene; and B is a heterocyclic group selected from triazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, benzothiazolyl, quinolyl and isoquinolyl, said heterocyclic group being optionally substituted by one or more alkyl, alkoxy, nitro or phenyl group, and the physiologically acceptable acid addition salts thereof. The compound of formula (I) are or cardiotonic activity and thus may be useful for the treatment of circulatory diseases.

Abstract: New intermediate, an optically active (1S,5R)-7,7-alkylenedioxy-2-alkoxycarbonylbicyclo[3.3.0]octan-3-one which is useful for the synthesis of an optically active carbacyclin. This intermediate is prepared, as a non-reduced compound, from a racemic compound, (1SR,5RS)-7,7-alkylenedioxy-2-alkoxycarbonyl-cis-bicyclo[3.3.0]octan-3-one , by treatment of the racemic compound with a microorganism. The microorganism has an ability of specifically reducing the keto group of the (1R,5S) epimer of the racemic compound.

Abstract: A new water-insoluble, modified gluten product is now provided, which is produced by kneading a mixture of wheat flour, L-ascorbic acid, cystine and water, and then fractionating the resulting kneaded, dough-like hydrated flour mixture, by repeated water washing, so as to recover a fraction comprising the water-insoluble modified gluten product from the dough. The modified gluten product now produced is useful as a bread improver. This new modified gluten product may further be mixed with cystine and an emulsifier to prepare a bread improver composition, which may be added to a farinaceous bread flour mixture or bread-making dough and is useful to improve the crumb texture, outer profile and crumb palatability of the bread products and also render the bread-making dough as made of the farinaceous bread flour mixture remarkably tolerant to the mechanical workings of the bread-making dough.

Abstract: Compounds are described of the formula ##STR1## wherein R.sub.1 is a nitro or trifluoromethyl group; R.sub.2 is a C.sub.1 -C.sub.6 alkyl group; R.sub.3 is a pyridyl or pyridyl N-oxide group which may be substituted with halogen, hydroxyl, haloalkyl, C.sub.1 -C.sub.6 alkoxy or C.sub.1 -C.sub.6 alkyl and further may be fused with a benzene or naphthalene ring, said ring being optionally substituted with C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, halogen or haloalkyl, and a pharmaceutically acceptable acid addition salt thereof. The compounds of the formula (I) are of vasodilating and blood pressure lowering activities and thus may be useful for the treatment of cardiac diseases, cerebrovascular diseases and hypertension.

Abstract: A new water-insoluble modified gluten product and a new water-soluble proteinaceous substance have now been found to be produced by kneading a mixture of wheat flour, one or more oxidizing agents such as L-ascorbic acid, potassium boromate, ammonium persulfate and potassium iodate, and water and then separating or fractionating the resulting dough-like or batter-like, hydrated flour mixture as kneaded, for instance, by repeated water-washing or centrifugation, so as to give individually a fraction comprising the water-insoluble modified gluten product, a fraction comprising an aqueous solution containing the water-soluble proteinaceous substance dissolved therein, and a fraction comprising the starchy substances and if necessary, subsequently dehydrating said aqueous solution.

Abstract: New intermediate, an optically active (1R,5S,6S,7R)-6-tert-butyldiphenylsilyloxmethyl-7-hydroxy-bicyclo[3.3.0]oc tan-3-one (I) having high optical purity which is useful for the synthesis of an optically active carbacyclin and an optically active pentalenolactone E methyl ester. The compound (I) is also an intermediate compound serving for the purpose of improving the optical purity of (1R,5S,6S,7R)-3,3-ethylenedioxy-6-hydroxymethyl-7-(2'-tetrahydropyranyloxy )bicyclo[3.3.0]octane. The compound (I) is prepared by reacting (1R,5S,6S,7R)-3,3-ethylenedioxy-6-hydroxymethyl-7-(2'-tetrahydropyranyloxy )bicyclo[3.3.0]octane with tert-butylchlorodiphenylsilane in the presence of a base and removing the ethylenedioxy and tetrahydropyranyl groups of the resultant compound under an acid condition.

Abstract: Now is provided a new sustained release drug preparation comprising such an inclusion complex of a medical compound with a hydrophobic cyclodextrin derivative, e.g. ethylated cyclodextrins, which sustains or retards the dissolution and release of the medical compound at a controlled rate from the inclusion complex and hence from the drug preparation containing the inclusion complex, so as to maintain the concentration of the medical compound in blood at an effective level for prolonged time. This drug preparation may further contain a second type of an inclusion complex of the medical compound with a hydrophilic cyclodextrin or hydrophilic cyclodextrin derivative, in mixture with the first type of the inclusion complex of the medical compound with a hydrophobic cyclodextrin derivative, to maintain the controlled release of the medical compound from the drug.

Abstract: 4(3H)-Quinazolinone derivatives of formula (I) are provided. ##STR1## wherein R.sub.1 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group, an aryl group, a substituted aryl group, or an aralkyl group; R.sub.2 is a C.sub.1 -C.sub.6 alkylamino group, a phenyl group, a substituted phenyl group, or a 5- or 6-membered heterocyclic group containing one or more N, O or S as a hetero atom or atoms, said heterocyclic group optionally being substituted or fused with a benzene ring; n is 1 or 2; or R.sub.2 represents a geranyl group or a dipyridylmethyl group together with the group --(CH.sub.2).sub.n --; and X is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or a halogen atom, and pharmaceutically acceptable acid addition salts thereof.They are useful as antiulcer agents.